Skip to main content

Table 3 Ongoing studies of immunotherapy in extensive stage small cell lung cancer

From: Emerging therapies for small cell lung cancer

Phase

Study

Treatment arms

ClinicalTrials.gov identifier

Estimated primary completion date

First line

 II

REACTION

Cisplatin/carboplatin + etoposide + pembrolizumab vs. cisplatin/carboplatin + etoposide

NCT02580994

August 2020

 III

CASPIAN

Durvalumab+ tremelimumab+ cisplatin/carboplatin + etoposide vs. durvalumab+ cisplatin/carboplatin + etoposide vs. cisplatin/carboplatin + etoposide

NCT03043872

September 2019

Maintenance

 III

CheckMate-451

Nivolumab vs. nivolumab + ipilimumab vs. placebo

NCT02538666

October 2018

Relapsed

 I/II

CheckMate-331

Nivolumab vs. topotecan vs. amrubicin

NCT02481830

August 2018

 II

Winship3112-15

Tremelimumab + durvalumab vs. tremelimumab + durvalumab + radiation

NCT02701400

January 2020

 II

AFT-17

Pembrolizumab vs. topotecan

NCT02963090

May 2019

 I/II

CA001-030

BMS-986012 vs. BMS-986012 ± nivolumab

NCT02247349

October 2019

 I/II

MEDIOLA

Durvalumab + olaparib vs. durvalumab + olaparib + bevacizumab

NCT02734004

March 2023